

PRESS RELEASE

Stockholm, 31 July 2014



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 31 July 2014 amounts to 270,785,950 shares, whereof 270,389,770 common shares and 396,180 class C shares, corresponding to in total 270,429,388 votes. The increase in the number of shares and votes results from an issue of 396,180 class C shares under Swedish Orphan Biovitrum's incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds 4,688,948 common shares and all 396,180 class C shares.

About Sobi

Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Inflammation and Genetic diseases, with two late stage biological development projects within Haemophilia. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2013, Sobi had total revenues of SEK 2.2 billion (\$334 M) and about 550 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.

For more information please contact

Media relations

Oskar Bosson, Head of Communications

T: +46 70 410 71 80

oskar.bosson@sobi.com

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 31 July 2014 at 08:00 CET.